Chemical Works of

Company snapshot

Chemical Works of is a pharma organization headquartered in EU. Primary therapeutic focus areas include Hypogonadism, Alzheimer's Disease. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (1).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Chemical Works of. Not investment advice.

• What is Chemical Works of?

  Chemical Works of is a pharma organization headquartered in EU. Primary therapeutic focus areas include Hypogonadism, Alzheimer's Disease. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov

• Is Chemical Works of publicly traded?

  Chemical Works of appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Chemical Works of develop or market?

  We link 1 drug profile(s) where Chemical Works of is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/chemical-works-of-gedeon-richter-plc-gedeon-richter-plc#company-drugs.

• What are the latest developments for Chemical Works of?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Chemical Works of focus on?

  Chemical Works of focuses on Hypogonadism, Alzheimer's Disease based on our analysis of their pipeline programs and drug development activities.